In This Section      

eIRB 2 Launch and Information Sessions

January 16, 2014

Dear Colleagues,

For the last few months, we have been testing and making final revisions to eIRB2, the updated online IRB submission system.  The eIRB2 system is replacing eIRB which is almost ten years old. eIRB2 is built on the same software platform, but incorporates newer and more advanced technology. 

We are planning to launch eIRB2 on Monday, January 27, 2014.  Prior to the launch, eIRB must be taken offline for a few days to migrate data to eIRB2.  eIRB will be taken offline on Friday, January 24 and will be back up on Monday, January 27.  All active protocols without a pending action will be migrated immediately to eIRB2.  Protocols with pending actions will not be migrated to eIRB2 until after the pending actions are complete in eIRB.  Terminated, expired, disapproved, and withdrawn applications will not be migrated to eIRB2.  They will remain in eIRB which will act as an archive and will be accessible to PIs and study team members.

Most of the changes in eIRB2 relate to performance.  However, users will notice the following improvements:

  • The recruitment and drugs/devices sections have been reworked to flow more smoothly.
  • Questions in the Protocol Events (formerly referred to as Problem Events) section are redesigned to help researchers determine whether it is necessary to submit an event immediately or with the continuing review application.
  • “Reviewer Notes” have replaced the “Respond to Issues” activity.  This new activity will allow study teams to respond to IRB issues directly in the relevant section of the application.

For more information about the changes in eIRB2 including an interactive tutorial see .

The eIRB system has become an essential component for conducting clinical research at Johns Hopkins. I’d like to thank you in advance for your patience while the transition is taking place. We are hopeful the transition to eIRB2 will be smooth, and we are confident the users will be pleased with the end product. 


Daniel E. Ford, M.D., M.P.H.
Vice Dean for Clinical Investigation